H

elix, the Silicon Valley company that’s styled itself as an app store for DNA tests, made a splash last week when it announced it had raised $200 million — the latest windfall for a company leveraging a boom in consumer genomics.

But as money sloshes around the industry, there’s an uneasy and unsettled question gnawing at even the most bullish investors: Are these bets going to pay off?

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Great reporting and a cool animated DNA/money graphic. You can look at it two ways: 1) money is “poring” into DTC genomics, or 2) investments are going down the well.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy